Skip to content

Net margin at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-30.9%-10.5pp
ALN
Alnylam PharmaceuticalsALNY
11.7%+8.0pp
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-13,856.5%-15,058pp
Beam Therapeutics logo
Beam TherapeuticsBEAM
-742.7%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-123.9%-28.4pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-508.5%-254pp

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's net margin?
Intellia Therapeutics (NTLA) reported net margin of -597% in Q1 2026.
How has Intellia Therapeutics's net margin changed year-over-year?
Intellia Therapeutics's net margin increased by 48.3% year-over-year, from -1,154.1% to -597%.
What is the long-term trend for Intellia Therapeutics's net margin?
Over 5 years (2020 to 2025), Intellia Therapeutics's net margin has grown at a 21.4% compound annual growth rate (CAGR), from -231.5% to -609.9%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.